Given the promising efficacy of JAK inhibitors in the treatment of COVID-19-induced ARDS, the potential therapeutic effect by targeting JAK/STAT signaling pathway in ARDS has been revealed and may become a new strategy for treating other types of ARDS. Here, SOAT1 is linked to COVID-19.